Close Menu

NEW YORK – Myriad Genetics reported after the close of the market on Tuesday that its fiscal fourth quarter revenues rose 11 percent year over year, but the company faced unanticipated reimbursement pressures that negatively impacted its fourth quarter and fiscal year revenues.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.